The trademark application RAXTEMY was filed by Mylan Institutional Inc., a U.S. corporation (the "Applicant"). The application was published for oppositions on May 18, 2020, and it was registered by office on August 25, 2020 without any oppositions.
The application was filed in English (German was selected as the second language).
Partial Surrender of the trademark registration was recorded on May 1, 2022.
Goods And Services
The mark was filed in class 5 with following description of goods:
Pharmaceuticals
Pharmaceutical and medical preparations
Pharmaceutical preparations for the treatment of cancer
Pharmaceutical preparations for the treatment of Non Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Pharmaceutical preparations for the treatment of rheumatoid arthritis, chronic plaque psoriasis, Crohn's disease, ankylosing spondylitis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis.